Evidence map›Paper›PMID 42502246›Full record

ArticleJournal of cellular and molecular medicine2026

Forebrain Lineage Factor DMRTA2 Is Not Required for Maintenance of H3G34-Mutant Paediatric High-Grade Gliomas.

Raul B Bressan, Oliva Sanchez, Carlos Alberto Oliveira de Biagi-Junior, Raúl Torres-Ruiz, Gustavo Alencastro Veiga Cruzeiro, Irene Salgado, Sandra Rodriguez-Perales, Eduardo Caleiras, Zaira Vega, Gillian Morrison and 3 more

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Raul B BressanSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0002-5673-9563
Oliva SanchezSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0009-0006-8001-9773
Carlos Alberto Oliveira de Biagi-JuniorDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-0700-3135
Raúl Torres-RuizSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0001-9606-0398
Gustavo Alencastro Veiga CruzeiroDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-0005-3984
Irene SalgadoSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0003-4708-5921
Sandra Rodriguez-PeralesSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0001-7221-3636
Eduardo CaleirasSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0001-8768-3630
Zaira VegaSpanish National Cancer Research Centre, Madrid, Spain.
Gillian MorrisonCentre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
Steven M PollardCentre for Regenerative Medicine, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
Mariella G FilbinDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
Manuel ValienteSpanish National Cancer Research Centre, Madrid, Spain.ORCID 0000-0002-0647-7542

Funding

Agencia Estatal de Investigación RYC2024-048827-IFundación Científica Asociación Española Contra el Cáncer PRYCO234528VALIFundación Científica Asociación Española Contra el Cáncer PRYGN259169VALIFundación Científica Asociación Española Contra el Cáncer TRNSC213878VALIFundacion la Caixa HR23-00051Instituto de Salud Carlos III AC20/00114Ministerio de Ciencia, Innovación y Universidades FPU22/03421Ministerio de Ciencia, Innovación y Universidades PI23/01932Ministerio de Ciencia, Innovación y Universidades PID2021-124582OB-I00
6 · The paper itself

Abstract

Developmental transcriptional programs are increasingly recognized as key drivers of paediatric gliomagenesis. Here, we unexpectedly find that the forebrain-specific doublesex- and mab-3-related transcription factor a2 (DMRTA2), despite being highly expressed in H3G34-mutant diffuse hemispheric glioma (DHG-H3G34) and implicated in tumour initiation, is not required for the maintenance of established patient-derived tumour cells. These findings support a stage-specific framework in which transcriptional dependencies are dynamically rewired during tumour progression in paediatric brain tumours.

Indexed as

Brain NeoplasmsGliomaHistonesMutationProsencephalonTranscription FactorsChildGene Expression Regulation, NeoplasticHumansNeoplasm GradingHistonesTranscription Factors

Identifiers

PMID42502246
PMCPMC13401718

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.